Trials / Completed
CompletedNCT02300844
Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- 22 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability and pharmacokinetics of single doses of NNC0174-0833 in normal weight, overweight to obese but otherwise healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NNC0174-0833 | Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833. Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated. |
| DRUG | placebo | Subjects will receive a single s.c. (subcutaneousl/under the skin) dose. |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-03-21
- Completion
- 2016-03-21
- First posted
- 2014-11-25
- Last updated
- 2018-01-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02300844. Inclusion in this directory is not an endorsement.